methyl 1-hydroxy-1,2,3,4-tetrahydronaphthalene-1-carboxylate | 1620-59-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: methyl 1-hydroxy-1,2,3,4-tetrahydronaphthalene-1-carboxylate
• 英文别名: 1-hydroxytetralin-1-yl-carboxylic acid, methyl ester；1-hydroxytetralin-1-yl-carboxylic acid,methyl ester；1-Hydroxy-tetralin-1-carbonsaeure-methylester；methyl 1-hydroxy-3,4-dihydro-2H-naphthalene-1-carboxylate
• CAS: 1620-59-3
• 化学式: C₁₂H₁₄O₃
• 分子量: 206.241
• InChiKey: UOVBMTIOIQCVBL-UHFFFAOYSA-N

物化性质

• 沸点：
  88-90 °C(Press: 0.15 Torr)
• 密度：
  1.218±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 1-hydroxy-1,2,3,4-tetrahydronaphthalene-1-carboxylate 以400 mg (17%)的产率得到1-Hydroxy-tetralin-1-carbonsaeure
  参考文献：
  名称：

  Amidino derivatives and their use as thrombin inhibitors

  摘要：

  提供了符合式I的化合物，其中R1、Rx、Y、Ry、n和B的含义如描述中所述，这些化合物可作为胰蛋白酶样蛋白酶的竞争性抑制剂，例如凝血酶，在需要抑制凝血酶的情况下特别适用（例如血栓形成），或作为抗凝剂。

  公开号：

  US06265397B1
• 作为产物：
  描述：

  1-ethynyl-1,2,3,4-tetrahydronaphthalen-1-ol 在 potassium permanganate 作用下， 以 乙醚 、 环己烷 为溶剂， 生成 methyl 1-hydroxy-1,2,3,4-tetrahydronaphthalene-1-carboxylate
  参考文献：
  名称：

  具有潜在拟精神活性的化合物的合成。3。

  摘要：

  DOI：

  10.1021/jm00328a007

文献信息

• [EN] SPIRO-OXAZOLONES<br/>[FR] SPIRO-OXAZOLONES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015091411A1

  公开（公告）日：2015-06-25

  The present invention provides spiro-oxazolones, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.

  本发明提供了螺环噁唑酮，其作为V1a受体调节剂，特别是作为V1a受体拮抗剂，其制备方法，含有它们的药物组合物以及它们作为药物的用途。本化合物在外周和中枢作用下，对于不当分泌加压素、焦虑、抑郁症、强迫症、自闭症谱系障碍、精神分裂症、攻击性行为和相位转移性睡眠障碍，特别是时差反应等症状的治疗具有用处。
• Electroreductive Acylation of Aromatic Ketones with Acylimidazoles
  作者：Naoki Kise、Syun Agui、Shinji Morimoto、Nasuo Ueda

  DOI：10.1021/jo051498w

  日期：2005.11.1

  The intermolecular reductive coupling of aromatic ketones with acylimidazoles was effected by electroreduction in the presence of chlorotrimethylsilane and gave α-trimethylsiloxy ketones and esters. The best result was obtained using Bu4NPF6 as a supporting electrolyte and a Pb cathode in THF. The α-trimethylsiloxy-containing products were transformed to the corresponding α-hydroxy ketones and esters

  在氯代三甲基硅烷的存在下，通过电还原作用实现芳族酮与酰基咪唑的分子间还原偶联，得到α-三甲基甲硅烷氧基酮和酯。使用Bu 4 NPF 6作为支持电解质和THF中的Pb阴极可获得最佳结果。通过在THF中用TBAF处理，将含α-三甲基甲硅烷氧基的产物转化为相应的α-羟基酮和酯。该方法对于δ-和ε-酮基酰基咪唑的分子内还原偶联也是有效的。
• New amidino derivatives and their use as thrombin inhibitors
  申请人：AstraZeneca AB

  公开号：US20020022612A1

  公开（公告）日：2002-02-21

  There is provided compounds of formula I, 1 wherein R 1 , R x , Y, R y , n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

  提供了化合物I,1的公式，其中R1、Rx、Y、Ry、n和B的含义如描述中所给，其可作为竞争性蛋白酶抑制剂，如凝血酶，尤其在需要抑制凝血酶的情况下（例如血栓形成）或作为抗凝剂的治疗中有用。
• Spiro-oxazolones
  申请人：Hoffmann-La Roche Inc.

  公开号：US10479796B2

  公开（公告）日：2019-11-19

  The present invention provides spiro-oxazolones, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.

  本发明提供了作为 V1a 受体调节剂，特别是作为 V1a 受体拮抗剂的螺噁唑酮类化合物、其制造方法、含有它们的药物组合物及其作为药物的用途。在血管加压素分泌不当、焦虑、抑郁障碍、强迫症、自闭症谱系障碍、精神分裂症、攻击行为和相移睡眠障碍（尤其是时差）等情况下，本化合物可作为外周和中枢作用的治疗药物。
• SPIRO-OXAZOLONES
  申请人：F.Hoffmann-La Roche AG

  公开号：EP3083633A1

  公开（公告）日：2016-10-26